Oligometastasis in Prostate Cancer: Can We Learn from Those "Excluded" from a Phase 2 Trial?
Metastasis-directed therapy
Oligometastasis
Positron emission tomography
Prostate cancer
Prostate-specific membrane antigen
Journal
European urology open science
ISSN: 2666-1683
Titre abrégé: Eur Urol Open Sci
Pays: Netherlands
ID NLM: 101771568
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
accepted:
24
03
2023
medline:
7
6
2023
pubmed:
7
6
2023
entrez:
7
6
2023
Statut:
epublish
Résumé
We conducted and previously published a phase 2 trial of metastasis-directed therapy (MDT) in men with recurrence of prostate cancer at a low prostate-specific antigen level following radical prostatectomy and postoperative radiotherapy. All patients had negative conventional imaging and underwent prostate-specific membrane antigen (PSMA) positron emission tomography (PET). Patients without visible disease ( In men with prostate cancer with rising PSA levels following surgery and radiation, a newer type of scan called PSMA-PET (prostate-specific membrane antigen positron emission tomography) can be used to characterize and differentiate the patterns of recurrence, and inform future cancer outcomes.
Identifiants
pubmed: 37284049
doi: 10.1016/j.euros.2023.03.016
pii: S2666-1683(23)00201-X
pmc: PMC10240507
doi:
Types de publication
Journal Article
Langues
eng
Pagination
79-84Informations de copyright
© 2023 The Author(s).
Références
Eur Urol. 2022 Dec;82(6):584-598
pubmed: 35995644
Eur Urol. 2021 Sep;80(3):374-382
pubmed: 33685838
Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):693-704
pubmed: 36031465
J Clin Oncol. 2017 Sep 20;35(27):3097-3104
pubmed: 28796587
Lancet Oncol. 2021 Mar;22(3):402-410
pubmed: 33662287
Eur Urol. 2022 Aug;82(2):e52-e53
pubmed: 35562268
BMJ Open. 2020 Apr 22;10(4):e035959
pubmed: 32327479
J Natl Cancer Inst. 2015 Sep 25;107(12):djv261
pubmed: 26409187